<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01611571</url>
  </required_header>
  <id_info>
    <org_study_id>AAAA4304</org_study_id>
    <nct_id>NCT01611571</nct_id>
  </id_info>
  <brief_title>Combination Risedronate - Parathyroid Hormone Trial in Male Osteoporosis</brief_title>
  <acronym>RPM</acronym>
  <official_title>Combination Risedronate - Parathyroid Hormone Trial in Male Osteoporosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Columbia University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Alliance for Better Bone Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Columbia University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to develop new treatment options for osteoporosis in men. The
      Investigators will study two medications and three treatment regimens. First, risedronate
      (FDA approved) will be studied as monotherapy. Second, the investigators will study
      injectable parathyroid hormone (PTH 134, teriparatide余 FDA approved), as a therapy for male
      osteoporosis. PTH, a naturally occurring hormone produced by the parathyroid glands, is one
      of the most important regulators of bone metabolism. The drug being studied in this protocol,
      teriparatide, is the first aminoterminal 34 amino acids of the native 84amino acid peptide.
      Teriparatide contains all of the classical biological activities of native PTH. In studies of
      postmenopausal women, in a small study of 23 men with osteoporosis and a larger study of 437
      men treatment with teriparatide led to significant increases in bone density. Although
      teriparatide and actonel are now approved for osteoporosis in men additional studies of these
      medications are needed in order to establish how best to use these drugs. This study is
      focused on an entirely new treatment approach, namely the combination of two medications for
      the treatment of osteoporosis risedronate with teriparatide to evaluate whether combination
      therapy is superior to therapy with either medication alone. This study is also designed to
      assess the extent to which risedronate maintains increases in bone density after a course of
      mono or combination therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Design:

      This study involves a 24month commitment, constituting 12 visits as outlined below. The study
      coordinator will contact patients remotely by phone or email at the Month 9 visit, the Month
      15, and the Month 21 visit so these do not require travel to Columbia University Medical
      Center.

      This randomized, doubleblind study has two phases. The first 18month phase has 3 arms.

      Patients will be randomized to receive either:

      Risedronate / arm 1余 33% of total number of patients Teriparatide / arm 2余 33% of total
      population or, The combination of Teriparatide and Risedronate / arm 3余 33% of total
      population.

      All patients will receive a daily subcutaneous injection with a small, 31 gauge needle
      (Teriparatide 20 ug or placebo vehicle), as well as a weekly pill (Risedronate 35 mg or
      placebo).

      The second phase of the study will last for 6 months. During this time, patients will stop
      their daily injections but will continue taking weekly pills. These pills will contain
      Risedronate for all patients.

      Thus, the second phase of the study, lasting 6 months, will have only one arm; that being,
      all participants will be on open label Risedronate for six months.

      TOTAL: 90 men

      Primary Endpoint: change in spine bone density in phase one of the study. The PRIMARY OUTCOME
      MEASURE in this study is the percentage change in lumbar spine bone density after 18 months
      of therapy comparing the three groups.

      Power analysis was conducted based upon ascertaining significance of change of the first 18
      months and the subsequent 6 months of the protocol. Based upon a 2-tailed test with an alpha
      of 0.05, the anticipated change in each of the three arms will be readily apparent at the
      lumbar spine with the &quot;n&quot; of 30 in each group.

      Secondary Endpoint: change in LS bone density at 24 months, change in hip and radius bone
      density in phase one and phase two of the study, change in bone markers, morphometric
      vertebral fractures at 18 months.

      VISIT ONE: Screening visit:

      At this visit study staff will review the Consent Form (patient and person obtaining consent
      sign the consent form) and inclusion/exclusion criteria. They will collect demographic
      information, medical history, treatment history for patient's osteoporosis, and prior
      medication history.

      Physical exam of the mouth, thyroid/neck, heart, lungs, abdomen, extremities, skin, mental
      status, sensory/motor status, lymph nodes, musculoskeletal, general appearance, height,
      weight, and blood pressure will be performed in order to identify any conditions which may
      exclude the potential participant from the study. This will be hereto forth referred to as
      &quot;Physical Exam&quot; Blood will be collected from the patient. A total of 2 tablespoons of blood
      by volume will be drawn from the patient to test for serum calcium, creatinine, parathyroid
      hormone, hepatic function, (Total Protein, Albumin, Globulin, A/G Ratio, Total Bilirubin,
      Direct Bilirubin, Alkaline Phosphatase, ALT, AST), and testosterone levels to determine the
      patient's eligibility for the study. Approximately 1.5 tablespoons of blood will be stored
      for research. The blood will be tested later for bone markers.

      Duration: approximately 3 hours

      VISIT TWO: Baseline/0 visit:

      On this day patients begin their medications. Patients will learn how to administer
      injections (Teriparatide) and take the study pill (Risedronate) and will receive their first
      6months worth of study supplies. The study drugs are managed by the Columbia University
      Research Pharmacy. The number of injection pens and the number of pills given to the patient
      will be recorded in case report forms. This will be hereto forth referred to as &quot;Study Drug
      Supply/ ReSupply&quot;. In addition to the study drugs, the patients will be required to take a
      multivitamin with at least 400 IU of vitamin D and at least 500 mg of calcium each day. This
      is considered standard of care for people with osteoporosis. The patient will be asked if
      he/she experiences leg cramps, fatigue, depression, constipation, increased urination, back
      pain/kidney stones, local irritation/inflammation at the injection site or difficulty
      swallowing/esophageal ulcers, or dental problems such as the need to have a tooth pulled,
      implant placed or other dental procedure, nonhealing mouth sore. The patient can respond that
      these symptoms are absent, mild, moderate, or severe. This information is collected as a
      baseline for comparison to symptoms that may develop as a consequence of study medication
      usage.

      This will be hereto forth referred to as &quot;Adverse Events&quot;. Patients are asked about any
      changes in supplementary or prescription medications since the last visit. Patients are asked
      about any changes in treatments for conditions old or new since the last visit. Patients are
      asked if any medical conditions or events have occurred or significantly changed since the
      last visit. All information will be recorded in case report forms. This will be hereto forth
      referred to as &quot;New Conditions/Con Meds&quot;.

      Blood will be collected from the patient. A total of 2 tablespoons of blood by volume will be
      drawn from the patient. Approximately 0.5 tablespoons of blood will be used to test blood
      calcium and creatinine to monitor the safety of the patient. This will be hereto forth
      referred to as &quot;Blood Calcium/Creatinine&quot;. Approximately 1.5 tablespoons of blood will be
      stored for research. The blood will be tested later for bone markers.

      This will be hereto forth referred to as &quot;Blood Storage.&quot; Urine will be collected from the
      patient. Urine will be collected over a 24hour period and stored for research and tested
      later for Calcium and Creatinine levels. This will be hereto forth referred to as &quot;24 Hour
      Urine&quot; Additionally, a spot urine sample will be collected from the patient at the visit.
      This will be stored for research and tested later for urine NTX. This will be hereto forth
      referred to as &quot;Urine Storage&quot; Xrays of the lumbar and thoracic spine (Lumbar and Thoracic AP
      and Lateral images) will be done to establish baseline fracture presence. This will be hereto
      forth referred to as &quot;XRay&quot;.

      Dual Xray Absorptiometry (DXA) will be performed to establish baseline bone density. This
      will be hereto forth referred to as &quot;BMD&quot; Duration: approximately 3 hours

      VISIT THREE: Week 1:

      Procedures that are repeated include Blood Calcium/Creatinine, Blood Storage, Urine Storage,
      24 Hour Urine, Adverse Events, and New Conditions/Con Meds Duration: approximately 30 minutes

      VISIT FOUR: Month 1:

      Procedures that are repeated include Blood Storage, Urine Storage, Adverse Events, and New
      Conditions/Con Meds Duration: approximately 30 minutes

      VISIT FIVE: Month 3:

      Procedures that are repeated include Blood Calcium/Creatinine, Urine Storage, Adverse Events,
      and New Conditions/ Con Meds Duration: approximately 30 minutes

      VISIT SIX: Month 6:

      Procedures that are repeated include Physical Exam, Study Drug Supply/ ReSupply, Blood
      Calcium/Creatinine, Blood Storage, Urine Storage, BMD, Adverse Events, and New Conditions/Con
      Meds Duration: approximately 1.5 hours.

      VISIT SEVEN: Month 9: phone visit:

      Procedures that are repeated include Adverse Events, and New Conditions/Con Meds.

      Duration: Approximately 15 minutes.

      VISIT EIGHT: Month 12:

      Procedures that are repeated include Study Drug Supply/ ReSupply, Blood Calcium/Creatinine,
      Blood Storage, Urine Storage, BMD, XRay, Adverse Events, and New Conditions/Con Meds
      Duration: approximately 2.5 hours.

      VISIST NINE: Month 15: phone visit:

      Procedures that are repeated include Adverse Events, and New Conditions/Con Meds Duration:
      Approximately 15 minutes.

      VISIT TEN: Month 18:

      Termination from phase 1 and entry into phase 2. Procedures that are repeated include
      Physical Exam, Blood Calcium/Creatinine, Blood Storage, Urine Storage, 24 Hour Urine, BMD,
      XRay, Adverse Events, and New Conditions/Con Meds. Study Drug Supply/ ReSupply will also
      occur. Of note, this will be Risedronate only, no more injectable medication). Patients
      therefore will only be given a supply of 6months worth of study pills.

      Duration: approximately 2.5 hours

      VISIT ELEVEN: Month 21: phone visit:

      Procedures that are repeated include Adverse Events, and New Conditions/Con Meds Duration:
      Approximately 15 minutes.

      VISIT TWELVE: Month 24: FINAL STUDY VISIT. Study physicians will discuss bone density results
      and recommend a course of poststudy treatment (if needed).

      Procedures that are repeated include Physical Exam, Blood Calcium/Creatinine, Blood Storage,
      Urine Storage, 24 Hour Urine, BMD, XRay, Adverse Events, and New Conditions/Con Meds.

      Termination from study occurs here. Duration: approximately 3.5 hours.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2003</start_date>
  <completion_date type="Actual">November 2011</completion_date>
  <primary_completion_date type="Actual">November 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Spine Bone Density</measure>
    <time_frame>18 months</time_frame>
    <description>change in spine bone density at 18 months measured by DXA 18 and 24 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Hip Bone Density</measure>
    <time_frame>baseline and 18 months</time_frame>
    <description>change in hip bone density measured by DXA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Forearm Bone Density</measure>
    <time_frame>baseline and 18 months</time_frame>
    <description>change in 1/3 radius of forearm bone density as measured by DXA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>New Morphometric Vertebral Fractures</measure>
    <time_frame>baseline through 18 months</time_frame>
    <description>counting the total new morphometric vertebral fractures as determined by x-ray from baseline through end of study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in FN BMD at 18 Months</measure>
    <time_frame>18 months</time_frame>
    <description>Change in the Femoral Neck BMD at 18 month</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Osteoporosis</condition>
  <arm_group>
    <arm_group_label>Active Risedronate Placebo Teriparatide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Active Risedronate + Placebo Teriparatide for 18 months / Active Risedronate for 6 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active Risedronate Active Teriparatide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Active Risedronate + Active Teriparatide for 18 months / Active Risedronate for 6 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Risedronate Active Teriparatide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Placebo Risedronate Active Teriparatide for 18 months / Active Risedronate for 6 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Risedronate</intervention_name>
    <description>weekly risedronate</description>
    <arm_group_label>Active Risedronate Placebo Teriparatide</arm_group_label>
    <arm_group_label>Active Risedronate Active Teriparatide</arm_group_label>
    <other_name>Actonel</other_name>
    <other_name>Risedronic Acid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Teriparatide</intervention_name>
    <description>daily teriparatide</description>
    <arm_group_label>Active Risedronate Active Teriparatide</arm_group_label>
    <arm_group_label>Placebo Risedronate Active Teriparatide</arm_group_label>
    <other_name>PTH1-34</other_name>
    <other_name>Forteo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Teriparatide</intervention_name>
    <description>daily placebo of teriparatide</description>
    <arm_group_label>Active Risedronate Placebo Teriparatide</arm_group_label>
    <other_name>Teriparatide</other_name>
    <other_name>PTH1-34</other_name>
    <other_name>Forteo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo Risedronate</intervention_name>
    <description>weekly placebo of Risedronic Acid</description>
    <arm_group_label>Placebo Risedronate Active Teriparatide</arm_group_label>
    <other_name>Risedronate</other_name>
    <other_name>Risedronic Acid</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Males, ages 30-85 with osteoporosis.

          2. Osteoporosis can be due to hypogonadism, past steroid use, or idiopathic.

          3. Patients with hypogonadism can be included if their replacement dosage of testosterone
             has been stable for at least 18 months.

          4. Bone mineral density must be 2 or more standard deviations below (T-score 2.0) the
             young adult peak for men at the lumbar spine, the hip or the radius.

          5. Normal renal (glomerular filtration rate &gt;= 60 ml/min) and liver (less than or equal
             to twice the normal limits for ALT and AST) function.

        Exclusion Criteria:

          1. Use of any specific osteoporosis drug in the previous 6 months.

          2. Known or suspected metabolic bone diseases (such as renal osteodystrophy,
             osteomalacia) other than osteoporosis.

          3. Preexisting hypercalcemia or an underlying hypercalcemic disorder, such as primary
             hyperparathyroidism.

          4. Secondary hyperparathyroidism.

          5. Paget's disease of bone or fibrous dysplasia. Teriparatide should not be given to
             patients with these conditions due to an increased risk of osteosarcoma.

          6. Patients with any elevations of alkaline phosphatase that are secondary to bone
             disease, as such individuals may be at risk for osteosarcoma.

          7. History or presence of any malignancy, except dermatological, but including melanoma.
             Known or suspected bone metastasis, or a history of skeletal malignancies.

          8. Prior radiation therapy. Patients with prior radiation therapy should be excluded from
             treatment with teriparatide.

          9. Any medical condition, which in the opinion of the investigator could preclude study
             participation, including but not limited to cardiovascular, gastric, renal and hepatic
             disorders, or abnormal PSA test. In particular, patients with active or recent (within
             the last 2 years) urolithiasis will be excluded.

         10. History of previous major bowel surgery including bowel resection.

         11. Oral use of systematic glucocorticoids for two or more weeks in the previous six
             months.

         12. Parenteral use of systemic glucocorticoids on more than two occasions in the previous
             six months.

         13. Use of anticonvulsant drugs.

         14. History of uncontrolled diabetes mellitus (Patient with Type 2 diabetes who have
             HbA1C&lt; 8 are permitted to be enrolled).

         15. Hypercalciuria (&gt; 4 mg/kg/day).

         16. Impaired liver function (&gt;twice the upper normal limits for ALT and AST).

         17. Hyperadrenalism as assessed by physical examination.

         18. Any other clinically significant laboratory abnormalities, which are deemed relevant
             to the design of the protocol.

         19. Patients with known hypersensitivity to any of the test materials (teriparatide or
             risedronate) or related components (metacresol, mannitol, glacial acetic acid, sodium
             acetate).

         20. Use of any investigational or unlicensed drug in the previous 30 days.

         21. Patients who may be unreliable for the study, including those engaging in excessive
             alcohol consumption or drug abuse or patients who are unable to return for scheduled
             follow-up visits.

         22. Patients who are unable or unwilling to comply fully with the protocol.

         23. Inability to stand or sit upright for at least 30 minutes

         24. Those with history of esophagitis, Barrett's esophagus, esophageal/peptic ulcers or
             esophageal motility disorders

         25. Hypocalcaemia

         26. Renal dysfunction (GFR &lt;60)

         27. Patients planning invasive dental work such as implants, extractions or procedures
             involving the jaw bone or patients with poor oral hygiene

         28. Use of digitalis.

         29. Patients with HIV/AIDS.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marcella Walker, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Columbia University Medical Center, Harkness Pavilion</name>
      <address>
        <city>New York City</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Walker MD, Cusano NE, Sliney J Jr, Romano M, Zhang C, McMahon DJ, Bilezikian JP. Combination therapy with risedronate and teriparatide in male osteoporosis. Endocrine. 2013 Aug;44(1):237-46. doi: 10.1007/s12020-012-9819-4. Epub 2012 Oct 26.</citation>
    <PMID>23099796</PMID>
  </results_reference>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 29, 2012</study_first_submitted>
  <study_first_submitted_qc>June 4, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 5, 2012</study_first_posted>
  <results_first_submitted>August 20, 2013</results_first_submitted>
  <results_first_submitted_qc>January 15, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 4, 2014</results_first_posted>
  <last_update_submitted>January 15, 2014</last_update_submitted>
  <last_update_submitted_qc>January 15, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 4, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Columbia University</investigator_affiliation>
    <investigator_full_name>Marcella Walker</investigator_full_name>
    <investigator_title>Irving Assistant Professor of Clinical Medicine</investigator_title>
  </responsible_party>
  <keyword>osteoporosis</keyword>
  <keyword>male</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
    <mesh_term>Teriparatide</mesh_term>
    <mesh_term>Risedronate Sodium</mesh_term>
    <mesh_term>Etidronic Acid</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>beginning 12/23/2003 and ending 11/2008 a total of 31 participants were enrolled in this study.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Active Risedronate + Active Teriparatide</title>
          <description>Active Risedronate Active Teriparatide
Risedronic acid &amp; teriparatide : weekly risedronate daily teriparatide</description>
        </group>
        <group group_id="P2">
          <title>Active Risedronte + Placebo Teriparatide</title>
          <description>Active Risedronte Placebo Teriparatide
Risedronic acid : weekly risedronate daily teriparatide (placebo)</description>
        </group>
        <group group_id="P3">
          <title>Placebo Risedronate + Active Teriparatide, Active Risedronate</title>
          <description>Placebo Risedronate Active Teriparatide for 18 months Active Risedronate for 6 months
Teriparatide : weekly risedronate (placebo) 18 months daily teriparatide 18 months weekly risedronate 6 months</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Active Risedronate Active Teriparatide</title>
          <description>Active Risedronate Active Teriparatide
Risedronic acid &amp; teriparatide : weekly risedronate daily teriparatide</description>
        </group>
        <group group_id="B2">
          <title>Active Risedronte Placebo Teriparatide</title>
          <description>Active Risedronte Placebo Teriparatide
Risedronic acid : weekly risedronate daily teriparatide (placebo)</description>
        </group>
        <group group_id="B3">
          <title>Placebo Risedronate Active Teriparatide, Active Risedronate</title>
          <description>Placebo Risedronate Active Teriparatide for 18 months Active Risedronate for 6 months
Teriparatide : weekly risedronate (placebo) 18 months daily teriparatide 18 months weekly risedronate 6 months</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="11"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="10"/>
            <count group_id="B4" value="31"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56.7" spread="4.9"/>
                    <measurement group_id="B2" value="54" spread="2"/>
                    <measurement group_id="B3" value="51.6" spread="3.9"/>
                    <measurement group_id="B4" value="51.6" spread="3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Spine Bone Density</title>
        <description>change in spine bone density at 18 months measured by DXA 18 and 24 months</description>
        <time_frame>18 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Active Risedronate Active Teriparatide</title>
            <description>Active Risedronate Active Teriparatide
Risedronic acid &amp; teriparatide : weekly risedronate daily teriparatide</description>
          </group>
          <group group_id="O2">
            <title>Active Risedronte Placebo Teriparatide</title>
            <description>Active Risedronte Placebo Teriparatide
Risedronic acid : weekly risedronate daily teriparatide (placebo)</description>
          </group>
          <group group_id="O3">
            <title>Placebo Risedronate Active Teriparatide</title>
            <description>Placebo Risedronate Active Teriparatide for 18 months Active Risedronate for 6 months
Teriparatide : weekly risedronate (placebo) 18 months daily teriparatide 18 months weekly risedronate 6 months</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Spine Bone Density</title>
          <description>change in spine bone density at 18 months measured by DXA 18 and 24 months</description>
          <units>% change in LS BMD</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.95" spread="1.9"/>
                    <measurement group_id="O2" value="3.76" spread="1.8"/>
                    <measurement group_id="O3" value="5.68" spread="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Hip Bone Density</title>
        <description>change in hip bone density measured by DXA</description>
        <time_frame>baseline and 18 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Active Risedronate Active Teriparatide</title>
            <description>Active Risedronate Active Teriparatide
Risedronic acid &amp; teriparatide : weekly risedronate daily teriparatide</description>
          </group>
          <group group_id="O2">
            <title>Active Risedronte Placebo Teriparatide</title>
            <description>Active Risedronte Placebo Teriparatide
Risedronic acid : weekly risedronate daily teriparatide (placebo)</description>
          </group>
          <group group_id="O3">
            <title>Placebo Risedronate Active Teriparatide</title>
            <description>Placebo Risedronate Active Teriparatide for 18 months Active Risedronate for 6 months
Teriparatide : weekly risedronate (placebo) 18 months daily teriparatide 18 months weekly risedronate 6 months</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Hip Bone Density</title>
          <description>change in hip bone density measured by DXA</description>
          <units>% change in TH BMD</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.86" spread="1.1"/>
                    <measurement group_id="O2" value="0.82" spread="0.95"/>
                    <measurement group_id="O3" value="0.29" spread="0.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Forearm Bone Density</title>
        <description>change in 1/3 radius of forearm bone density as measured by DXA</description>
        <time_frame>baseline and 18 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Active Risedronate Active Teriparatide</title>
            <description>Active Risedronate Active Teriparatide
Risedronic acid &amp; teriparatide : weekly risedronate daily teriparatide</description>
          </group>
          <group group_id="O2">
            <title>Active Risedronte Placebo Teriparatide</title>
            <description>Active Risedronte Placebo Teriparatide
Risedronic acid : weekly risedronate daily teriparatide (placebo)</description>
          </group>
          <group group_id="O3">
            <title>Placebo Risedronate Active Teriparatide</title>
            <description>Placebo Risedronate Active Teriparatide for 18 months Active Risedronate for 6 months
Teriparatide : weekly risedronate (placebo) 18 months daily teriparatide 18 months weekly risedronate 6 months</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Forearm Bone Density</title>
          <description>change in 1/3 radius of forearm bone density as measured by DXA</description>
          <units>% change in 1/3 Radius BMD</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" spread="0.6"/>
                    <measurement group_id="O2" value="0.11" spread="0.77"/>
                    <measurement group_id="O3" value="0.02" spread="0.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>New Morphometric Vertebral Fractures</title>
        <description>counting the total new morphometric vertebral fractures as determined by x-ray from baseline through end of study</description>
        <time_frame>baseline through 18 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Active Risedronate Active Teriparatide</title>
            <description>Active Risedronate Active Teriparatide
Risedronic acid &amp; teriparatide : weekly risedronate daily teriparatide</description>
          </group>
          <group group_id="O2">
            <title>Active Risedronte Placebo Teriparatide</title>
            <description>Active Risedronte Placebo Teriparatide
Risedronic acid : weekly risedronate daily teriparatide (placebo)</description>
          </group>
          <group group_id="O3">
            <title>Placebo Risedronate Active Teriparatide</title>
            <description>Placebo Risedronate Active Teriparatide for 18 months Active Risedronate for 6 months
Teriparatide : weekly risedronate (placebo) 18 months daily teriparatide 18 months weekly risedronate 6 months</description>
          </group>
        </group_list>
        <measure>
          <title>New Morphometric Vertebral Fractures</title>
          <description>counting the total new morphometric vertebral fractures as determined by x-ray from baseline through end of study</description>
          <units>vertebral fracture</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in FN BMD at 18 Months</title>
        <description>Change in the Femoral Neck BMD at 18 month</description>
        <time_frame>18 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Active Risedronate Active Teriparatide</title>
            <description>Active Risedronate Active Teriparatide
Risedronic acid &amp; teriparatide : weekly risedronate daily teriparatide</description>
          </group>
          <group group_id="O2">
            <title>Active Risedronte Placebo Teriparatide</title>
            <description>Active Risedronte Placebo Teriparatide
Risedronic acid : weekly risedronate daily teriparatide (placebo)</description>
          </group>
          <group group_id="O3">
            <title>Placebo Risedronate Active Teriparatide</title>
            <description>Placebo Risedronate Active Teriparatide for 18 months Active Risedronate for 6 months
Teriparatide : weekly risedronate (placebo) 18 months daily teriparatide 18 months weekly risedronate 6 months</description>
          </group>
        </group_list>
        <measure>
          <title>Change in FN BMD at 18 Months</title>
          <description>Change in the Femoral Neck BMD at 18 month</description>
          <units>% change in TH BMD</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.45" spread="1.8"/>
                    <measurement group_id="O2" value="0.5" spread="1.7"/>
                    <measurement group_id="O3" value="3.89" spread="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>each participant was enrolled for a total of 24 months and adverse events were collected throughout the entirety of their participation.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Active Risedronate Active Teriparatide</title>
          <description>Active Risedronate Active Teriparatide
Risedronic acid &amp; teriparatide : weekly risedronate daily teriparatide</description>
        </group>
        <group group_id="E2">
          <title>Active Risedronte Placebo Teriparatide</title>
          <description>Active Risedronte Placebo Teriparatide
Risedronic acid : weekly risedronate daily teriparatide (placebo)</description>
        </group>
        <group group_id="E3">
          <title>Placebo Risedronate Active Teriparatide, Active Risedronate</title>
          <description>Placebo Risedronate Active Teriparatide for 18 months Active Risedronate for 6 months
Teriparatide : weekly risedronate (placebo) 18 months daily teriparatide 18 months weekly risedronate 6 months</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Fracture, vertebral</sub_title>
                <description>new vertebral fracture</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastroesophageal Reflux</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="4" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Difficulty Swallowing</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fracture, patella</sub_title>
                <description>fracture of the left patella. This fracture not deemed to be a fragility fracture or in any way related to study drug or participation in the study.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Leg Cramping</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <description>participants experienced either leg cramping for the first time, or worsening of existing leg cramping</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Injection Site Irritation</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E2" events="6" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Marcella Walker MD</name_or_title>
      <organization>Columbia University Medical Center</organization>
      <phone>212-342-5351</phone>
      <email>mad2037@columbia.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

